Literature DB >> 26655032

Continuous versus intermittent infusion of vancomycin in adult patients: A systematic review and meta-analysis.

Jing-Jing Hao1, Han Chen2, Jian-Xin Zhou3.   

Abstract

Continuous infusion of vancomycin (CIV) and intermittent infusion of vancomycin (IIV) are two major administration strategies in clinical settings. However, previous articles comparing the efficacy and safety of CIV versus IIV showed inconsistent results. Therefore, a meta-analysis was conducted to compare the efficacy and safety of CIV and IIV. PubMed, the Cochrane Library and Web of Science up to June 2015 were searched using the keywords 'vancomycin', 'intravenous', 'parenteral', 'continuous', 'intermittent', 'discontinuous', 'infusion', 'administration' and 'dosing'. Eleven studies were included in the meta-analysis. Neither heterogeneity nor publication bias were observed. Patients treated with CIV had a significantly lower incidence of nephrotoxicity compared with patients receiving IIV [risk ratio (RR)=0.61, 95% confidence interval (CI) 0.47-0.80; P<0.001]. No significant difference in treatment failure between the two groups was detected. Mortality between patients receiving CIV and patients receiving IIV was similar (RR=1.15, 95% CI 0.85-1.54; P=0.365). This meta-analysis showed that CIV had superior safety compared with IIV, whilst the clinical efficacy was not significantly different. A further multicentre, randomised controlled trial is required to confirm these results.
Copyright © 2015 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Clinical efficacy; Continuous infusion; Infection; Intermittent infusion; Safety; Vancomycin

Mesh:

Substances:

Year:  2015        PMID: 26655032     DOI: 10.1016/j.ijantimicag.2015.10.019

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  23 in total

1.  Prospective Trial on the Use of Trough Concentration versus Area under the Curve To Determine Therapeutic Vancomycin Dosing.

Authors:  Michael N Neely; Lauren Kato; Gilmer Youn; Lironn Kraler; David Bayard; Michael van Guilder; Alan Schumitzky; Walter Yamada; Brenda Jones; Emi Minejima
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

2.  A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity.

Authors:  Natalie A Finch; Evan J Zasowski; Kyle P Murray; Ryan P Mynatt; Jing J Zhao; Raymond Yost; Jason M Pogue; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

3.  The Pharmacodynamic-Toxicodynamic Relationship of AUC and C max in Vancomycin-Induced Kidney Injury in an Animal Model.

Authors:  Sean N Avedissian; Gwendolyn Pais; Jiajun Liu; J Nicholas O'Donnell; Thomas P Lodise; Michael Neely; Walter C Prozialeck; Peter C Lamar; Leighton Becher; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

Review 4.  Rationalizing antimicrobial therapy in the ICU: a narrative review.

Authors:  Jean-François Timsit; Matteo Bassetti; Olaf Cremer; George Daikos; Jan de Waele; Andre Kallil; Eric Kipnis; Marin Kollef; Kevin Laupland; Jose-Artur Paiva; Jesús Rodríguez-Baño; Étienne Ruppé; Jorge Salluh; Fabio Silvio Taccone; Emmanuel Weiss; François Barbier
Journal:  Intensive Care Med       Date:  2019-01-18       Impact factor: 17.440

Review 5.  [Therapeutic drug monitoring and individual dosing of antibiotics during sepsis : Modern or just "trendy"?]

Authors:  A Brinkmann; A C Röhr; A Köberer; T Fuchs; J Preisenberger; W A Krüger; O R Frey
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-09-13       Impact factor: 0.840

Review 6.  Outpatient parenteral antimicrobial therapy and antibiotic stewardship: opponents or teammates?

Authors:  Ester Steffens; Charlotte Quintens; Inge Derdelinckx; Willy E Peetermans; Johan Van Eldere; Isabel Spriet; Annette Schuermans
Journal:  Infection       Date:  2018-11-15       Impact factor: 3.553

Review 7.  Continuous Infusion Vancomycin in Pediatric Patients: A Critical Review of the Evidence.

Authors:  Heather L Girand
Journal:  J Pediatr Pharmacol Ther       Date:  2020

Review 8.  Vancomycin Dosing and Monitoring: Critical Evaluation of the Current Practice.

Authors:  Fawzy Elbarbry
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-06       Impact factor: 2.441

9.  Currently used dosage regimens of vancomycin fail to achieve therapeutic levels in approximately 40% of intensive care unit patients.

Authors:  Vitor Yuzo Obara; Carolina Petrus Zacas; Claudia Maria Dantas de Maio Carrilho; Vinicius Daher Alvares Delfino
Journal:  Rev Bras Ter Intensiva       Date:  2016 Oct-Dec

Review 10.  The Nephrotoxicity of Vancomycin.

Authors:  E J Filippone; W K Kraft; J L Farber
Journal:  Clin Pharmacol Ther       Date:  2017-06-05       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.